You searched for book - Page 7 of 31

FDA warns more perinatal cell therapy firms: RenatiLabs & Cell Genuity

August 31, 2023 / Professor Paul Knoepfler, Ph.D. / 7 Comments

Starting last year the FDA has focused much of its cell therapy oversight resources on birth-related firms, including both clinics and suppliers. The latest warnings went to RenatiLabs & Cell Genuity. Warnings to unproven perinatal cell therapy firms Earlier this summer the agency warned Regenative Labs. There have been quite a few letters to others in this […]

FDA warns more perinatal cell therapy firms: RenatiLabs & Cell Genuity Read More »

Review of new David Sinclair paper, supplements & anti-aging glitz

July 18, 2023 / Professor Paul Knoepfler, Ph.D. / 8 Comments

Who is David Sinclair and why is he all over the media related to anti-aging efforts? This post is my effort to fact-check Sinclair’s statements in the context of the broader rejuvenation arena. In the process I also review his most recent paper from my view as a stem cell and cancer biologist interested in

Review of new David Sinclair paper, supplements & anti-aging glitz Read More »

Што се матични клетки?

June 28, 2023 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

Што се матични клетки? (Editor’s note: this is another in our series of stem cell outreach posts. This one provides key information on stem cells in Macedonian.) Што се матични клетки? Што се матични клетки? | Зошто се важни матичните клетки? | Видови на матични клетки | Што се иПМ клетки? | Иднината на терапиите

Што се матични клетки? Read More »

Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s

March 26, 2023 / Professor Paul Knoepfler, Ph.D. / 2 Comments

It’s been almost seventeen years that I’ve been a professor here at UC Davis Medical School. It feels like home. I enjoy teaching our first-year medical students each year. Some end up doing research in my lab. Our school recently got a nice write-up over at STAT News by Usha Lee McFarling on the diversity

Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s Read More »

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui

March 19, 2023 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall

Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »

Weekly reads: stem cell niche & AI stumble on health

February 12, 2023 / Professor Paul Knoepfler, Ph.D. / 2 Comments

What is a stem cell niche? It’s the home of stem cells. The stem cell niche is a fascinating environment. It has many constituents that impact stem cell behavior and even eventual stem cell transplant functions. In today’s weekly reads, we’ll start with the niche as there have been several interesting papers on this topic. The

Weekly reads: stem cell niche & AI stumble on health Read More »

Desperately seeking stem cells: celeb quests for elixirs often mislead

January 10, 2023 / Professor Paul Knoepfler, Ph.D. / 3 Comments

What could go wrong with celebrities desperately hunting for stem cells as a fountain of youth? A flaskful of problems. Some famous folks can’t seem to get enough of stem cells, even if those supposed therapies are unproven and risky. In recent years, dozens of celebs have gotten stem cell procedures of various kinds. The

Desperately seeking stem cells: celeb quests for elixirs often mislead Read More »

Weekly reads: Gamida Cell, Siddhartha Mukherjee, CRISPR in viruses

November 27, 2022 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Hematopoietic stem cells have many clinical applications and a company called Gamida Cell has an interesting product in this area called Omidubicel that may have several applications. I’m going to start the weekly reads with news there. Gamida Cell and the FDA A recent piece discussed how Omidubicel is progressing with the FDA. FDA extends

Weekly reads: Gamida Cell, Siddhartha Mukherjee, CRISPR in viruses Read More »

Updates on CRISPR therapy development and clinical trials

November 22, 2022 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

When I first heard of CRISPR gene editing I was excited for my lab to try it out, but it seemed a long way from the field having even one CRISPR therapy available to treat human disease. In the Knoepfler lab, we study genetic and genomic programming in human development and disease. Gene editing seemed

Updates on CRISPR therapy development and clinical trials Read More »

Stem cells & the philosopher’s stone, P53, thyroid organoids

November 20, 2022 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

I hadn’t remembered the history of the philosopher’s stone until reading a new review article about stem cells and aging. Here’s the article. Is the philosopher’s stone to rejuvenate blood stem cells an epigenetic regulator? Nature Aging. This preview kind of piece discusses how inhibiting a specific factor called PHF6 can “rejuvenate” HSCs in mice.

Stem cells & the philosopher’s stone, P53, thyroid organoids Read More »

Search Results for: book